Medivir makes change within the management team


Stockholm, Sweden — Medivir AB (OMX: MVIR) announces a reorganization of the
management team in order to streamline and increase operational focus. After the
change the company´s management team consists of 6 people, including the CEO,
vs. previously 8 people. Two new functions are created: Strategic Business
Development, which is a consolidation of Corporate Development and Business
Development, and Finance & Administration, which is a consolidation of the
current Finance & Administration function and Corporate Affairs & IR.

-     I want to create a smaller and more effective management team with fewer
and stronger functions. With the structure and composition of the management
team now being presented, I am convinced that we will be able to work in a more
focused way and deliver better results in the implementation of the updated
strategy and in the leadership of the company, says Niklas Prager, CEO Medivir
AB.

The management team will be strengthened with two new colleagues with long
experience from strategic business development as well as finance. Christine
Lind has been recruited as new head of Strategic Business Development. New CFO,
with responsibility also for IR, will be Ola Burmark.

Christina Kassberg, Rein Piir, Paul Wallace and Håkan Wallin have chosen to
leave the company by the end of February. The new organization will be effective
on March 1, 2015.

-     I would like to take this opportunity to thank the four colleagues that
are leaving the company for their great dedication and valuable contributions
throughout the years, Niklas Prager continues.

For more information please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30.

About Medivir
Medivir is an emerging and profitable research‐based pharmaceutical company with
an established marketing and sales organisation in the Nordic region with a
broad portfolio of prescription pharmaceuticals.
Medivir receives royalties from Johnson & Johnson on the global sales of the
hepatitis C pharmaceutical, OLYSIO®. In addition, revenues for sales of OLYSIO
in the Nordic region are generated through the company’s own sales and marketing
organisation. Medivir’s research and development portfolio of pharmaceuticals is
based on the company’s expertise within protease inhibitor design and
nucleoside/nucleotide science. The company’s research and development focus is
within infectious diseases and oncology and the on-going clinical projects in
osteoarthritis and neuropathic pain.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Attachments

01218297.pdf